Form 8-K - Current report:
SEC Accession No. 0001193125-24-138936
Filing Date
2024-05-15
Accepted
2024-05-15 08:30:32
Documents
15
Period of Report
2024-05-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d820660d8k.htm   iXBRL 8-K 32579
2 EX-99.1 d820660dex991.htm EX-99.1 12887
6 GRAPHIC g820660dsp6.jpg GRAPHIC 7926
  Complete submission text file 0001193125-24-138936.txt   183044

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA teva-20240515.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20240515_lab.xml EX-101.LAB 17167
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20240515_pre.xml EX-101.PRE 10792
19 EXTRACTED XBRL INSTANCE DOCUMENT d820660d8k_htm.xml XML 3614
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 24947336
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)